PRIMARY CARE PALLIATIVE CARE FORMULARY

Transcription

1 PRIMARY CARE PALLIATIVE CARE FORMULARY This formulary has been developed between West Essex CCG and the palliative care team at St Clare Hospice. The aim of the formulary is to ensure that medicines use is both clinically appropriate and cost-effective. The pharmacy will only routinely supply medicines included in the formulary because they have been determined to be the most appropriate in terms of efficacy, safety, patient acceptability, convenience and economy. GP advice line: run 24/7 at St Clare Hospice providing advice on symptom management. Phone: The drugs are classified as follows: GREEN Appropriate for prescribing by General Practice at the request of the palliative care service. AMBER Prescribing should only be undertaken in General Practice with a shared care agreement in place (likely to be outside of clinical competences). RED Should only be prescribed at the request of a multidisciplinary team and should not be prescribed in General Practice. Monitoring will be carried out on a monthly basis: FP10s will be monitored via epact. Medicines supplied for in-patient use will be monitored via invoices submitted to West Essex CCG. Use of medicines outside the terms of the license (i.e. off-label ) may be judged by the prescriber to be in the best interest of the patient. DRUG INDICATION ANY OTHER INDICATION DOSE ANALGESICS Buprenorphine patches Moderate to Severe Pain Titrate through dose range COMMENT BuTrans (7d release patch) for moderate, non-malignant pain unresponsive to non-opioid analgesics and Transtec (96h release patch) for moderate to severe chronic cancer pain and severe pain unresponsive to non-opioid analgesics. At low dose step 2 of WHO ladder and at higher dose, it would be 3rd step for WHO ladder. Buprenorphine is highly lipid-soluble making it suitable for TD delivery. Usual maximum dose is 140mcg/h. Appears to acts as full agonist in therapeutic range; other opioids can be used for breakthrough pain. 1

2 Co-codamol 30/500 Mild to Moderate pain 1 to 2 every 4hrs Max: 8 in 24hrs Codeine Phosphate Mild to Moderate pain Diarrhoea Cough Pain: 30 to 60 mg every 4hrs Max daily dose: 240 mg Diarrhoea: 30 mg qds Cough: 5 to 10 ml (linctus) qds Fentanyl patches Severe pain Transdermal systems Requires titration Morphine all presentations Moderate to Severe Pain Breathlessness Cough Diarrhoea Titrate dose Usual starting dose: 5 to 10 mg every 4hrs Oxycodone all presentations Moderate to Severe Pain Breathlessness Titrate dose Usual starting dose: 2.5 to 5 mg every 4hrs Paracetamol Mild to Moderate pain Fever PO or PR: 0.5 to 1 g every 4 to 6hrs Effervescent only in dysphagia. Approximately one tenth potency of morphine. Some Caucasians are poor metabolisers of codeine, other ethnic groups may be extensive or ultra-metabolisers. Combination product (Codeine + Paracetamol). Approximately one tenth potency of morphine. Some Caucasians are poor metabolisers of codeine, other ethnic groups may be extensive or ultra-metabolisers. Where transdermal fentanyl is necessary, prescribe a matrix patch. Durogesic, Matrifen, Mezolar, Osmanil and Vitanyl are interchangeable and the product with the lowest acquisition cost should be used. 72h release patch. Local recommendation: prescribe Matrifen. Brand prescribing recommended. Immediate release preparations Oramorph solution, Sevredol and for modified release preparations Zomorph capsules (except 5mg - only available as MST tablets). Reduce dose in the elderly and patients with renal impairment. Morphine intolerant only. Prescribe Longtec for the MR form and Shortec for immediate release. Reduce dose in the elderly and patients with renal impairment. Soluble only in dysphagia. Max dose 4 g in 24hrs Tramadol Moderate to Severe Pain 50 to 100 mg qds Max dose 400 mg/d Prescribe Marol for the MR form. At low dose step 2 of WHO ladder and at higher dose, it would be 3rd step for WHO ladder. Alfentanyl Moderate to severe pain, especially in renal impairment and constipation Requires titration Typical starting dose 250 to 500mcg SC prn or 1mg/24h CSCI A synthetic fentanyl derivative with a more rapid onset of action, a shorter duration of action, and a potency approximately 25% that of fentanyl. Usually reserved for patients unable to tolerate morphine or diamorphine (e.g. renal failure) 1 mg alfentanil 10 mg diamorphine. Diamorphine Moderate to Severe Pain Breathlessness Requires titration CSCI: typical starting dose 10mg to 20mg/24h Often preferred for injection because, being more soluble, it can be given in a smaller volume. Reduce dose in the elderly and patients with renal failure. 2

3 Fentanyl sublingual tablet Breakthrough cancer pain Trans-mucosal systems Requires titration Abstral only when oral morphine not suitable (if more than 4 episodes of breakthrough pain each day, background pain control should be adjusted). Trans-mucosal opioids are licensed for breakthrough cancer pain in patients on background opioid maintenance therapy. It is not possible to ensure interchangeability of the different formulations hence if switching re-titration is recommended. Nefopam Moderate pain Initial dose 30 mg tds Relief of persistent pain unresponsive to other non-opioid analgesics. Methadone Severe pain Linctus available for cough Titrated Consider prescribing a laxative with the above medications (excluding Paracetamol) due to constipating effect ANALGESICS - Neuropathic pain Amitriptyline Neuropathic pain Depression Bladder spasm Depression: 75 to 100 mg/d Neuropathic pain: start 10 to 25 mg titrate to 75 mg Capsaicin cream Neuropathic pain 0.025% (Zacin ) or 0.075% (Axsain ) cream Apply sparingly up to tds/qds (not more often than every 4 h) Pregabalin Neuropathic pain Partial seizures Anxiety Initial dose range 25 mg od to 75 mg bd Lidocaine patches Neuropathic pain 5% w/w lidocaine (700 mg) 1 to 3 patches for 12 h a day Exceptional complex patients unresponsive to other opioids. Long half-life. Can be used in renal failure. Caution if switching from another opioid as conversion factor highly variable and often dose dependant. Switching is best done with specialist support and if possible as an inpatient. Blocks the presynaptic re-uptake of serotonin and noradrenaline. Adjuvant analgesic for neuropathic pain. Analgesic effect usually seen at lower doses and more quickly than antidepressant effect; anticholinergic adverse effects may be troublesome. Affects the synthesis, storage, transport and release of substance P in pain fibres. Start with lowest strength and wear gloves to administer. NB/ A self-adhesive patch containing capsaicin 8% (Qutenza ) is licensed for the treatment of peripheral neuropathic pain in nondiabetic patients restricted use. Dose optimisation using the most appropriate strength. In normal renal function: 75 mg bd on day 1, 150 mg bd daily on days 3 7, then 300 mg bd days 10 14, then increased according to response > Max dose 600 mg/d OR 25 mg on on day 1, 25 mg bd on day 2, 75 mg bd on days 6 7, then increase by 25 mg bd every 2 days as needed to a maximum of 600 mg/d. Versatis - only for use in localised pain in patients unable to take oral medication due to a medical condition/disability. Post-herpetic neuralgia: apply plaster to intact, dry, non-hairy, nonirritated skin od for up to 12 h, followed by a 12-h plaster-free period; discontinue if no response after 4 weeks. Up to 3 plasters may be used to cover large areas; plasters may be cut. 3

4 ANALGESICS - NSAIDs Ibuprofen Mild to Moderate pain Inflammation Initial dose 300 to 400mg tds/qds Naproxen Mild to Moderate pain Inflammation PO: 0.5 to 1 g/d in 1 or 2 divided doses Diclofenac Mild to Moderate pain Inflammation PO or PR: 75 to 150mg/d in divided doses Celecoxib Mild to Moderate pain Inflammation Initial dose 100 mg bd and increase to 200 mg bd if required ANTIEMETICS Cyclizine po inj Nausea & vomiting 50 to 100 mg PO or SC 100 to 150 mg/24h via CSCI. Max daily PO/SC dose: 200 mg Has the lowest risk of serious GI side effects. Can be increased if necessary to max. 2.4 g/d; maintenance dose of g/d may be adequate. Modified release preparation available (Brufen Retard 800 mg, Fenbid Spansule 300 mg). Use IR unless clinical rationale for SR formulation. Intermediate risk of serious GI side effects prescribe with PPI. CV risk. Consider PPI if risk of peptic ulceration. Use IR unless clinical rationale for SR formulation. Associated with increased risk of thrombotic events thus not common practice to be initiated in the community. Discontinue after two weeks if no response. Useful for vomiting due to GI causes, or raised intracranial pressure. SC route may cause skin reactions. Can precipitate with Buscopan if both given in syringe driver. Domperidone po Nausea & vomiting 10 to 20 mg qds Prokinetic Not recommended for patients with underlying cardiac disease, risk of prolonged cardiac conduction intervals, congestive heart failure or already taking medications known to cause prolonged QT intervals. Also avoid in bowel obstruction. Haloperidol po inj Nausea & vomiting Psychosis Hiccup Restlessness Agitation Delirium Levomepromazine po inj Nausea, vomiting and sedative effect Psychosis Terminal agitation Anti-emetic: initial dose 1.5 mg/d Anti-psychotic: initial dose 5 mg/d Intractable hiccup: initial dose 1.5 mg/d PO: 3 mg od/bd SC: 6 to 12.5 mg CSCI: 12.5 to 75 mg Anti-emetic: initial dose 1.5 mg/d stat & typical maintenance dose 1.5 to 3 mg/d; if necessary, increase dose progressively to 5 to 10 mg/d. Anti-psychotic: initial dose 5 mg stat (1.5 mg in the elderly) and if necessary, increase daily dose progressively to 20 to 30 mg in divided doses. If the patient does not settle with 20 mg/d, consider prescribing a benzodiazepine concurrently. Intractable hiccup: maintenance dose 1.5 to 3 mg/d. Nozinan / Restricted: Levinan (unlicensed & expensive; order for named patient only). First-line anti-emetic, start with 3 mg od/bd and if necessary, increase to 6 mg od/bd. Second line anti-emetic starting with 6 to 12.5 mg PO/SC stat, and if necessary, increasing to 25 to 50 mg/24h. Terminal agitation or delirium: starting dose 25 mg SC and 50 to 75 mg/24h CSCI titrated according to response; maximum 300 mg/24h, occasionally more. 4

5 Metoclopramide po inj Nausea & vomiting Dyspepsia Reflex Hiccups Ondansetron po inj ANXIETY Diazepam all presentations Chemotherapy-induced nausea & vomiting Anxiety Insomnia Muscle spasm Pruritus Myoclonus Seizures PO: 10 to 20 mg qds CSCI: 30 to 100 mg/24h PO: 8 mg bd/tds SC: 8 mg bd/tds PR: 16 mg/d CSCI: 8 to 24 mg/d Pruritus: 4 to 8 mg bd/tds Initial dose 2mg and titrate depending on effect for each indication Prokinetic Gastric irritation: 10 mg PO qds or 40 to 60 mg/24h CSCI; prescribe appropriate gastro-protective drug. Delayed gastric emptying: 10mg PO qds or 40 to 100 mg/24h CSCI. Nausea and vomiting: 10 to 20 mg qds Increases gastric motility and gastric emptying. Use cautiously in GI obstruction. Modified release preparation available (Maxolon SR 15 mg). Use IR unless clinical rationale for SR formulation. If a 5-HT3-receptor antagonist is not clearly effective within 3 d, it should be discontinued. If clearly of benefit, continue indefinitely unless the cause is selflimiting. Benzodiazepine with GABA-potentiating actions in the CNS. Long plasma half-life and several active metabolites. Anxiety: 2 to 10 mg PO, usual range 2 to 20 mg PO. Muscle spasm: 2 to 5 mg PO, usual range 2 to 20 mg PO. Anticonvulsant: 10 mg PR/IV, usual range 10 to 30 mg. Rectal solutions available. Short-term use only. Buspirone Anxiety Initial dose 5 mg tds Non-sedating anxiolytic. Response to treatment may take up to 2 weeks, discontinue if not effective. CONSTIPATION Bisacodyl po pr Stimulant laxative Oral: 5 to 20 mg od/bd PR: 10 mg prn Oral formulation works within 12hrs, rectal formulation within one hour. Avoid in bowel obstruction. Should be given in combination with Glycerol suppositories. Glycerol suppositories Lubricant laxative, also 4gm supp. od to bd Should be given in combination with Bisacodyl suppositories. Stimulant laxative Liquid paraffin Faecal softener 5 to 20 ml bd Enhanced absorption with Docusate. Macrogols Bowel cleansing Chronic constipation: 1 to 3 sachets/d Faecal impaction: 8 sachets/d Prescribe Laxido Inert polymers of ethylene glycol which sequester fluid in the bowel. Chronic constipation, 1 to 3 sachets daily in divided doses usually for up to 2 w; contents of each sachet dissolved in half a glass (approx. 125 ml) of water; maintenance, 1 to 2 sachets/d Faecal impaction: 8 sachets/d dissolved in 1 l of water and drunk within 6 h, usually for max. 3 d. 5

6 Phosphate enema Osmotic laxative 1 od Draws additional water from the bloodstream into the colon to increase the effectiveness of the enema, but can be rather irritating to the colon, causing intense cramping or "griping." 2nd line. Sodium citrate Osmotic laxative 1 od Micralax micro-enema - 2nd line. Docusate sodium Stimulant laxative PO: 100 mg bd and titrated to maximum dose 200 mg tds Soften stools and is weak stimulant. Acts in 1 to 2 days. Do not give with liquid paraffin. Rectal preparations not indicated if haemorrhoids or anal fissure. Senna liquid Stimulant laxative PO: 7.5 to 15 mg on 2nd line - only if Bisacodyl is unsuitable. Higher doses frequently used by patients on opioids. Max dose 30 mg on but up to 60 mg reported. Often used on combination with a stool softener. Stimulant laxatives increase intestinal motility and often cause abdominal cramp; they should be avoided in intestinal obstruction. Arachis oil enema Faecal softener 1 PRN max od For faecal impaction. Acts by lubricating and softening the faeces, and promoting bowel movement. Avoid in peanut allergy or Inflammatory bowel disease. Methylnaltrexone Opioid-induced constipation Initial dose 8 mg (patients weighing 38 to 61 kg) or 12 mg (patients weighing 62 to 114 kg) DRY MOUTH Biotène oral balance Relief of dry mouth Apply up to 6 times a day Saliveze oral spray Relief of dry mouth Apply up to 6 times a day Initially give a single dose on alternate days. If there is no response, a second dose can be given after 24 h, but not more often. Alternatively the interval can be extended. About 50% patients defaecate within 4 h of a dose without impairment of analgesia or the development of withdrawal symptoms. Common undesirable effects include abdominal pain, diarrhoea, flatulence, and nausea. In severe renal impairment (creatinine clearance <30ml/min), the dose should be reduced. It is contra-indicated in the presence of known or suspected GI obstruction. Triple enzyme product Used for dry mouth caused by medications, diabetes, drug or radiation therapies, stress and depression. Aqueous solution of electrolytes present in concentrations similar to those found in human saliva. Used for dry mouth including dry mouth secondary to radiotherapy. EXCESSIVE SECRETIONS Glycopyrronium inj Excessive respiratory secretions SC: 0.2 to 0.4 mg CSCI: 0.6 to 1.2 mg/24h Occasionally doses of up to 2 mg tds are needed. Can cause inflammation at the injection site. 6

7 Hyoscine butylbromide inj Buscopan Hyoscine hydrobromide inj Excessive respiratory secretions Excessive respiratory secretions Smooth muscle spasm Nausea Vomiting Sweating Motion sickness Drooling Smooth muscle spasm Nausea Vomiting Sweating Smooth muscle colic: start with 20 mg SC stat and 60 mg/24h CSCI Secretions: start with 20 mg SC stat, 20 to 60 mg/24h CSCI Drooling: hyoscine hydrobromide 1 mg/72h TD Secretions: 400 mcg SC stat Smooth muscle colic: start with 20 mg SC stat and 60 mg/24h CSCI and if necessary, increase to 120 mg/24h max dose 300 mg/24h. Some centres add octreotide 300 to 500mcg/24h if hyoscine butylbromide 120 mg/24h fails to relieve symptoms adequately. For patients with obstructive symptoms without colic, metoclopramide should be tried before an antimuscarinic drug because the obstruction is often more functional than organic. Secretions: start with 20 mg SC stat, 20 to 60 mg/24h CSCI, and 20mg SC q1h prn. Some centres use higher doses, namely 60 to 120mg/24h CSCI. Secretions: Initial dose 400 mcg SC stat and then continue with 1200 mcg/24h CSCI, if necessary, increase to 2000 mcg/24h CSCI repeat 400 mcg prn. Some centres use hyoscine butylbromide instead. It is cheaper than hyoscine hydrobromide. Other options include glycopyrronium. GASTRO-INESTINAL TRACT Hyoscine butylbromide Buscopan Antispasmodic & malignant bowel obstruction Secretions See under excessive secretions (above) Lansoprazole Anti-ulcer agent 15 to 30 mg od Orodispersible tablets should only be used when the patient has swallowing difficulties. Loperamide Acute diarrhoea Chronic diarrhoea Faecal incontinence 2 to 4 mg stat Acute diarrhoea, 4 mg initially followed by 2 mg after each loose stool for up to 5 days; usual dose 6 to 8 mg/d; max. 16 mg/d. Chronic diarrhoea: initially, 4 to 8 mg/d in divided doses, subsequently adjusted according to response and given in 2 divided doses for maintenance; max. 16 mg/d. Faecal incontinence [unlicensed indication], initially 500 mcg/d, adjusted according to response; max. 16 mg/d in divided doses. Adverse effects include abdominal cramps, dizziness, drowsiness, and skin reactions. Mebeverine Antispasmodic 135 mg tds Musculotropic antispasmodic drug without anticholinergic sideeffects. Should be taken 20 minutes before meals. Pancreatin Steatorrhoea Treatment of exocrine pancreatic insufficiency 1 to 2 capsules with meals Creon 10,000 Creon 25,000 Creon 40,000 Initiated at the lowest recommended dose and gradually increased. The dosage of Creon should be individualized based on clinical symptoms, the degree of steatorrhoea present, and the fat content of the diet. 7

8 Octreotide Malignant bowel obstruction Vomiting Diarrhoea Bronchorrhoea Ascites Rectal discharge Intestinal obstruction: 250 to 500 mcg/d Ascites: 200 to 600 mcg/d Bronchorrhoea: 300 to 500 mcg/d Intractable diarrhoea: 50 to 500 mcg/d Intestinal obstruction: increasing to a max 750 mcg/d, occasionally higher. Intractable diarrhoea: increasing to a max 1500 mcg/d, occasionally higher. Once improvement in the symptom is achieved, reduction to the lowest dose that maintains symptom control can be tried. A depot formulation of octreotide 10 to 30 mg, given every 4 w is available and may be of use in patients with a chronic intestinal fistula or intractable diarrhoea. Ranitidine inj Anti-ulcer agent Itching 50 mg to 150 mg bd 100 to 300 mg in CSCI MISCELLANEOUS Aspirin Anticoagulation 75 to 150 mg od Only to be used when PPI is inappropriate to use. Dexamethasone po inj Alendronic acid Nausea & vomiting, neuropathic pain, raised intracranial pressure due to cerebral oedema, anorexia, dyspnoea, SCC, SVCO Bone pain & hypercalcaemia Used for symptoms associated with pressure from tumour mass effect Osteoporosis Daily dose ranges from 2mg to 16mg depending indication 10 mg od 70 mg weekly Appetite and fatigue: 2 to 4 mg Nerve compression, vomiting, breathlessness: 8 to 12 mg. SCC, SCVO, raised intracranial pressure: 16 mg (sometimes higher). Metabolism accelerated by carbamazepine and phenytoin (reduced effect). Doses best given in the morning. Can be delivered by CSCI. Consider PPI if risk of peptic ulceration. Remember to give patient a steroid card. Tablets should be swallowed whole with plenty of water while standing or sitting. To be taken on an empty stomach 30 minutes before breakfast or other oral medications. Continue to sit up for 30 minutes after oral intake (breakfast or oral medication) as well. Enoxaparin Anticoagulation DVT: 1.5 mg/kg/24 hours Increased risk of bleeding in renal impairment and those who are underweight or overweight. Dose and duration in Palliative care to be carefully supervised. Ibandronic acid po Bone pain & hypercalcaemia 50 mg od Renal failure only. Prescribe generically. Tablets should be swallowed whole with plenty of water while standing or sitting. To be taken on an empty stomach 30 minutes before breakfast or other oral medications. Continue to sit up for 30 minutes after oral intake (breakfast or oral medication) as well. Beware of Osteonecrosis of Jaw. Zoledronic acid inj Bone pain & hypercalcaemia 4 to 8 mg every 4 to 6 w Inhibitor of osteoclastic bone resorption. Max response for hypercalcaemia seen after 4 days. Relief for bone pain can take up to 14 days. Osteonecrosis of the jaw a potential complication. 8

9 SEDATIVES Haloperidol po inj Acute agitation & confusion Lorazepam po inj Anxiety & insomnia Seizures Insomnia Anxiety Agitation See also under antiemetics Midazolam inj Agitation Seizures Terminal agitation Intractable hiccup Nausea Vomiting Myoclonus Anti-emetic: initial dose 1.5 mg/d Anti-psychotic: initial dose 5 mg/d Intractable hiccup: initial dose 1.5 mg/d Anti-emetic: initial dose 1.5mg/d stat & typical maintenance dose 1.5 to 3mg/d; if necessary, increase dose progressively to 5 10mg/d Anti-psychotic: initial dose 5 mg stat (1.5 mg in the elderly) and if necessary, increase daily dose progressively to 20 to 30 mg in divided doses. If the patient does not settle with 20 mg/d, consider prescribing a benzodiazepine concurrently. Intractable hiccup: maintenance dose 1.5 to 3 mg/d. 1 to 4 mg od/bd Insomnia: 2 to 4mg PO. Anxiety: 1 mg SL/PO stat and bd, if necessary, increase to 2 to 6 mg/24h. Acute psychotic agitation: 2 mg PO every 30 min until the patient is settled; often used with haloperidol or risperidone to control psychotic agitation. SC: 5mg stat & prn doses Myoclonus: 10 to 30 mg CSCI. Seizures: 30 to 60 mg CSCI. Terminal agitation: 30 to 60 mg CSCI. If the patient does not settle on 30 mg/24h, an antipsychotic (e.g. haloperidol) is best introduced before further increasing the dose of midazolam. Hiccup: 30 to 60 mg CSCI. Nausea/Vomiting: 10 to 20 mg/24h CSCI. Midazolam can be given buccally (unlicensed route). A buccal liquid is available as an unlicensed special order (see Supply), or the contents of an ampoule for injection can be used. Zopiclone Insomnia 3.75 to 7.5 mg on Non-benzodiazepine hypnotic agent used in the treatment of insomnia. Side effects of taste disturbances including bitter metallic taste not uncommon. Prepared by: Dr. Qamar Abbas, Deputy Medical Director, St Clare Hospice Lucy Wright, Prescribing Support Pharmacy Technician, WECCG Reviewed by: Dr. John Zeppetella, Medical Director, St Clare Hospice Anurita Rohilla, Chief Pharmacist, WECCG May 2014 Approved by West Essex Clinical Commissioning Group Medicines Management Board on 12 th June 2014 To be reviewed May 2016 Reference: Palliative care in Clinical Practice. By Zeppetella G. ISBN ISBN (ebook). Springer-Verlag London